As normal p53 function is frequently lost in breast cancer, we began by determining whether or not the overexpression of Bcl3 negatively impacted the survival of patients receiving DNA-damaging agents and whether or not this depended on the p53 status of their tumours. The gene discussed is TP53; the disease is breast carcinoma.